tegafur has been researched along with Blood Diseases in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "One patient with colorectal cancer experienced a partial response and 9 patients with non-small cell lung, colorectal and gastro-oesophageal junction carcinomas had disease stabilisation lasting 4-26 (median 6) cycles." | 2.71 | Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. ( Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS, 2004) |
| " Therapy was therefore designed with an oral drug daily given in combination with RT in order to determine the efficacy and toxicity." | 2.71 | [Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer]. ( Molnár, J; Nagy, B; Paczona, R; Rovó, L; Thurzó, L, 2004) |
| " The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15." | 2.70 | A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. ( Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K, 2002) |
| " We aimed to assess the clinical efficacy and safety of S-1 combined with paclitaxel (PTX) for AGC by performing a systematic review and meta-analysis of the published studies." | 2.61 | S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis. ( Bian, NN; Min, GT; Wang, YH, 2019) |
| " Severe adverse events were observed in 22 patients (91." | 1.42 | Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015) |
| " Five patients showed grade 3 and 4 adverse reactions, all hematological." | 1.35 | Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. ( Ishikawa, K; Suzuki, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, NN | 1 |
| Wang, YH | 1 |
| Min, GT | 1 |
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 1 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 1 |
| Koike, K | 1 |
| Suzuki, S | 3 |
| Honda, K | 1 |
| Sato, T | 1 |
| Yamazaki, K | 1 |
| Ishikawa, K | 2 |
| Meulendijks, D | 1 |
| Henricks, LM | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 1 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 1 |
| Kleiblova, P | 1 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 1 |
| van Kuilenburg, AB | 1 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Beijnen, JH | 1 |
| Cats, A | 1 |
| Schellens, JH | 1 |
| Soh, J | 1 |
| Okumura, N | 1 |
| Nakata, M | 1 |
| Nakamura, H | 1 |
| Fukuda, M | 1 |
| Kataoka, M | 1 |
| Kajiwara, S | 1 |
| Sano, Y | 1 |
| Aoe, M | 1 |
| Kataoka, K | 1 |
| Hotta, K | 1 |
| Matsuo, K | 1 |
| Toyooka, S | 1 |
| Date, H | 1 |
| Kobayashi, S | 1 |
| Ueno, M | 1 |
| Hara, H | 1 |
| Irie, K | 1 |
| Goda, Y | 1 |
| Moriya, S | 1 |
| Tezuka, S | 1 |
| Tanaka, M | 1 |
| Okusaka, T | 1 |
| Ohkawa, S | 1 |
| Morimoto, M | 1 |
| Choi, IS | 1 |
| Lee, KW | 1 |
| Kim, KH | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Lee, JS | 1 |
| Sunaga, T | 1 |
| Harada, N | 1 |
| Hayashi, T | 1 |
| Suzuki, M | 1 |
| Shiroyama, T | 1 |
| Komuta, K | 1 |
| Imamura, F | 1 |
| Hirashima, T | 1 |
| Kijima, T | 1 |
| Tachibana, I | 1 |
| Kawase, I | 1 |
| Veronese, ML | 1 |
| Stevenson, JP | 1 |
| Sun, W | 1 |
| Redlinger, M | 1 |
| Algazy, K | 1 |
| Giantonio, B | 1 |
| Hahn, S | 1 |
| Vaughn, D | 1 |
| Thorn, C | 1 |
| Whitehead, AS | 1 |
| Haller, DG | 1 |
| O'Dwyer, PJ | 1 |
| Nagy, B | 1 |
| Molnár, J | 1 |
| Rovó, L | 1 |
| Paczona, R | 1 |
| Thurzó, L | 1 |
| Kim, SJ | 1 |
| Seo, HY | 1 |
| Choi, JG | 1 |
| Sul, HR | 1 |
| Sung, HJ | 1 |
| Park, KH | 1 |
| Choi, IK | 1 |
| Oh, SC | 1 |
| Yoon, SY | 1 |
| Seo, JH | 1 |
| Choi, CW | 1 |
| Kim, BS | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Chen, YM | 1 |
| Perng, RP | 1 |
| Tsai, CM | 1 |
| Whang-Peng, J | 1 |
| Kaira, K | 1 |
| Sunaga, N | 1 |
| Yanagitani, N | 1 |
| Imai, H | 1 |
| Utsugi, M | 1 |
| Shimizu, Y | 1 |
| Iijima, H | 1 |
| Tomizawa, Y | 1 |
| Hisada, T | 1 |
| Ishizuka, T | 1 |
| Saito, R | 1 |
| Mori, M | 1 |
| Chang, PM | 1 |
| Chen, PM | 1 |
| Chu, PY | 1 |
| Wang, LW | 1 |
| Tai, SK | 1 |
| Tsai, TL | 1 |
| Huang, JL | 1 |
| Wang, YF | 1 |
| Chang, SY | 1 |
| Yang, MH | 1 |
| Vestermark, LW | 1 |
| Jacobsen, A | 1 |
| Qvortrup, C | 1 |
| Hansen, F | 1 |
| Bisgaard, C | 1 |
| Baatrup, G | 1 |
| Rasmussen, P | 1 |
| Pfeiffer, P | 1 |
| Seto, T | 1 |
| Yoh, K | 1 |
| Asoh, H | 1 |
| Yamamoto, H | 1 |
| Semba, H | 1 |
| Ichinose, Y | 1 |
2 reviews available for tegafur and Blood Diseases
| Article | Year |
|---|---|
S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hematologic Diseases; Humans; Oxo | 2019 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
13 trials available for tegafur and Blood Diseases
| Article | Year |
|---|---|
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deox | 2016 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Surviv | 2011 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dos | 2004 |
[Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 2004 |
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antineoplastic Agents; Antineoplastic Combined | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car | 2007 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2008 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 2002 |
3 other studies available for tegafur and Blood Diseases
| Article | Year |
|---|---|
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot | 2015 |
Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Sq | 2009 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |